Total Payments
$10,535
2024 Payments
$916.73
Companies
50
Transactions
675
Medicare Patients
9,061
Medicare Billing
$1.3M
Payment Breakdown by Category
Food & Beverage$9,873 (93.7%)
Travel$398.32 (3.8%)
Education$263.99 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,873 | 641 | 93.7% |
| Travel and Lodging | $398.32 | 2 | 3.8% |
| Education | $263.99 | 32 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,756 | 124 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,009 | 83 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $822.12 | 54 | $0 (2024) |
| Amgen Inc. | $781.40 | 51 | $0 (2024) |
| PFIZER INC. | $668.38 | 41 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $530.13 | 31 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $476.92 | 33 | $0 (2024) |
| Medtronic, Inc. | $447.41 | 6 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $353.32 | 21 | $0 (2019) |
| Lundbeck LLC | $319.25 | 29 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $916.73 | 41 | Novartis Pharmaceuticals Corporation ($276.56) |
| 2023 | $1,382 | 74 | E.R. Squibb & Sons, L.L.C. ($340.93) |
| 2022 | $1,302 | 80 | Novartis Pharmaceuticals Corporation ($282.96) |
| 2021 | $1,516 | 69 | Medtronic, Inc. ($447.41) |
| 2020 | $539.97 | 39 | Novartis Pharmaceuticals Corporation ($130.98) |
| 2019 | $1,836 | 159 | Novartis Pharmaceuticals Corporation ($263.71) |
| 2018 | $1,541 | 104 | Amgen Inc. ($234.40) |
| 2017 | $1,501 | 109 | Janssen Pharmaceuticals, Inc ($325.18) |
All Payment Transactions
675 individual payment records from CMS Open Payments — Page 2 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/15/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/09/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/08/2024 | Celgene Corporation | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.93 | General |
| Category: Cardiovascular | ||||||
| 04/22/2024 | Edwards Lifesciences Corporation | SAPIEN 3 Ultra RESILIA (Device) | Food and Beverage | In-kind items and services | $24.70 | General |
| Category: Transcatheter Heart Valves | ||||||
| 04/17/2024 | Edwards Lifesciences Corporation | — | Food and Beverage | In-kind items and services | $126.69 | General |
| 04/10/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 04/03/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/29/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: Not Applicable | ||||||
| 02/28/2024 | Celgene Corporation | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.31 | General |
| Category: Cardiovascular | ||||||
| 02/24/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 02/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 02/01/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $21.62 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/31/2024 | Celgene Corporation | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $17.80 | General |
| Category: Cardiovascular | ||||||
| 01/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/09/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/22/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $26.51 | General |
| Category: Cardiovascular | ||||||
| 12/22/2023 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: WATCHMAN_IC | ||||||
| 12/12/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/07/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/27/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| Category: Cardiovascular | ||||||
| 11/14/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/02/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/31/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/25/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $20.88 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,961 | 2,884 | $759,365 | $266,387 |
| 2022 | 28 | 2,227 | 3,408 | $923,450 | $336,162 |
| 2021 | 29 | 2,516 | 3,701 | $875,259 | $313,818 |
| 2020 | 28 | 2,357 | 3,598 | $947,477 | $343,869 |
Total Patients
9,061
Total Services
13,591
Medicare Billing
$1.3M
Procedure Codes
113
All Medicare Procedures & Services
113 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 61 | 61 | $134,200 | $67,947 | 50.6% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 61 | 120 | $84,000 | $50,089 | 59.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 278 | 469 | $119,524 | $40,419 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 239 | 360 | $69,105 | $21,927 | 31.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 123 | 127 | $88,900 | $17,846 | 20.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 74 | 106 | $39,410 | $13,400 | 34.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 63 | 252 | $20,412 | $11,110 | 54.4% |
| 78434 | Nuclear medicine study of heart muscle blood flow by pet | Office | 2023 | 58 | 58 | $29,000 | $5,980 | 20.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 96 | 98 | $22,050 | $5,017 | 22.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 78 | 79 | $20,540 | $4,199 | 20.4% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 41 | 69 | $12,672 | $3,722 | 29.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 272 | 331 | $14,962 | $3,225 | 21.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $9,544 | $2,985 | 31.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 43 | 131 | $12,707 | $2,684 | 21.1% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 53 | 167 | $14,529 | $2,655 | 18.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 33 | 33 | $9,900 | $2,368 | 23.9% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 76 | 79 | $19,750 | $2,202 | 11.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $6,341 | $2,056 | 32.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 23 | $4,715 | $1,419 | 30.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 18 | $5,292 | $1,308 | 24.7% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 21 | 24 | $6,984 | $1,151 | 16.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 25 | $3,750 | $1,060 | 28.3% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 143 | 153 | $6,273 | $879.28 | 14.0% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 29 | 31 | $2,325 | $482.57 | 20.8% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 29 | 31 | $2,480 | $252.72 | 10.2% |
About Dr. Deborah Hughes, M.D
Dr. Deborah Hughes, M.D is a Cardiovascular Disease healthcare provider based in Salem, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619949401.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deborah Hughes, M.D has received a total of $10,535 in payments from pharmaceutical and medical device companies, with $916.73 received in 2024. These payments were reported across 675 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($9,873).
As a Medicare-enrolled provider, Hughes has provided services to 9,061 Medicare beneficiaries, totaling 13,591 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 113 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Salem, OR
- Active Since 02/06/2006
- Last Updated 07/11/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1619949401
Products in Payments
- ENTRESTO (Drug) $1,472
- ELIQUIS (Drug) $1,194
- XARELTO (Drug) $1,009
- VenaSeal (Device) $421.96
- Corlanor (Drug) $411.63
- Repatha (Biological) $358.78
- BRILINTA (Drug) $341.75
- NORTHERA (Drug) $319.25
- JARDIANCE (Drug) $299.78
- LEQVIO (Drug) $268.92
- LifeVest (Device) $263.55
- PRALUENT (Drug) $263.51
- VERQUVO (Drug) $256.67
- Livalo (Drug) $241.40
- Carospir (Drug) $209.78
- PRADAXA (Drug) $207.53
- Vascepa (Drug) $196.83
- CAMZYOS (Drug) $189.11
- SAMSCA (Drug) $168.02
- FARXIGA (Drug) $147.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Salem
Kevin Thompson, Do, DO
Cardiovascular Disease — Payments: $101,034
Cardiovascular Disease $101,034
Ashit Patel, M.d, M.D
Cardiovascular Disease — Payments: $54,451
Cardiovascular Disease $54,451
Dr. Sandeep Saha, M.d, M.D
Cardiovascular Disease — Payments: $43,942
Cardiovascular Disease $43,942
Dr. Andrew Maiolo, Md, MD
Cardiovascular Disease — Payments: $19,968
Cardiovascular Disease $19,968
Maziar Azadpour, M.d, M.D
Cardiovascular Disease — Payments: $17,622
Cardiovascular Disease $17,622
Barath Krishnamurthy, Md, MD
Cardiovascular Disease — Payments: $13,695
Cardiovascular Disease $13,695